The University of Chicago Medicine Comprehensive Cancer Center, Chicago
UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
UChicago Medicine Orland Park, Orland Park

Набор участниковФаза 1/2

Возраст от 18 лет · Любой пол · Обновлено 30 сент. 2026 г. · NCT05868226

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

University of Chicago Medical Center /ID# 271688, Chicago
Hope And Healing Cancer Services /ID# 271562, Hinsdale

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 28 сент. 2026 г. · NCT06820463

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Illinois Cancer Specialists, Arlington Heights
Illinois CancerCare - Bloomington, Bloomington
Illinois Cancer Specialists, Chicago
и еще 10

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 28 сент. 2026 г. · NCT07222800

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, Chicago

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT06218914

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

University of Chicago, Chicago

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT06004245

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Illinois Cancer Specialists, Arlington Heights
Illinois CancerCare, Peoria

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT06750094

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

City of Hope at Chicago, Zion

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT07271355

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Illinois Cancer Specialists, Arlington Heights
Illinois CancerCare, Peoria

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT06662786

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Northwestern University, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
Northwestern Medicine Cancer Center Old Irving Park, Chicago

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 24 сент. 2026 г. · NCT05863195

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Local Institution - 0433, Chicago

Набор участниковФаза 2/3

Возраст от 18 лет · Любой пол · Обновлено 23 сент. 2026 г. · NCT07221357

Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery

University of Chicago, Chicago

Набор участниковФаза 1/2

Возраст от 18 лет · Любой пол · Обновлено 21 сент. 2026 г. · NCT06349590

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Sih Cancer Institute, Carterville
University of Illinois Cancer Center, Chicago
Alexian Brothers Medical Center, Elk Grove Village
и еще 2

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 15 сент. 2026 г. · NCT07284849

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Illinois Cancer Specialists, Arlington Heights

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 11 сент. 2026 г. · NCT04929223

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Orchard Healthcare Research Inc., Skokie

Набор участниковНаблюдательное исследование

Возраст от 18 лет · Любой пол · Обновлено 11 сент. 2026 г. · NCT05935384

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Illinois Cancer Specialists, Arlington Heights
Illinois CancerCare PC, Peoria
Springfield Clinic, Springfield

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 9 сент. 2026 г. · NCT07549412

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Memorial Hospital East, Shiloh

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 9 сент. 2026 г. · NCT06696768

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Clinical Study Site, Chicago
Clinical Study Site, Elmhurst
Clinical Study Site, O'Fallon

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 8 сент. 2026 г. · NCT07228832

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Insight Research Institute, Chicago

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 3 сент. 2026 г. · NCT06252649

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Lurie Children's Hospital-Chicago, Chicago

Набор участниковФаза 1/2

12 Months – 30 Years · Любой пол · Обновлено 25 авг. 2026 г. · NCT04851119

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Research Site, Chicago

Набор участниковФаза 2

Возраст от 18 до 130 · Любой пол · Обновлено 18 авг. 2026 г. · NCT06792695

Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients

City of Hope at Chicago, Zion

Набор участников

Возраст от 18 лет · Любой пол · Обновлено 12 авг. 2026 г. · NCT07125729

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Orchard Healthcare Research Inc, Skokie

Набор участниковФаза 1/2

Возраст от 18 лет · Любой пол · Обновлено 5 авг. 2026 г. · NCT06330064

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Hope and Healing Cancer Services, Hinsdale

Набор участниковФаза 1/2

Возраст от 18 лет · Любой пол · Обновлено 30 июл. 2026 г. · NCT04657068

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago
Hope and Healing Cancer Services, Hinsdale
Orchard Healthcare Research, Skokie

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 15 июл. 2026 г. · NCT06937177

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

University of Chicago Medical Center /ID# 274742, Chicago

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 10 июл. 2026 г. · NCT07023289

Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection

Northwestern University-Comprehensive Transplant Center, Chicago

Набор участниковНаблюдательное исследование

Возраст от 18 лет · Любой пол · Обновлено 10 июл. 2026 г. · NCT06698146

CARE Tool Study Aim 3

Alton Memorial Hospital, Alton

Набор участников

Возраст от 18 лет · Любой пол · Обновлено 8 июл. 2026 г. · NCT07296887

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Hope and Healing Cancer Services, Hinsdale

Набор участниковФаза 4

Возраст от 18 лет · Любой пол · Обновлено 7 июл. 2026 г. · NCT06562543

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The University of Chicago Medical Center - Oncology, Chicago

Набор участниковФаза 1/2

Возраст от 18 лет · Любой пол · Обновлено 2 июл. 2026 г. · NCT07169734

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Context Investigational Site, Chicago

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 12 июн. 2026 г. · NCT06756035

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

Illinois Cancer Specialists, Arlington Heights

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 12 июн. 2026 г. · NCT07011576

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

OSF Healthcare Cancer Institute, Peoria

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 2 июн. 2026 г. · NCT06917079

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine University of Chicago Medicine, Chicago

Набор участниковНаблюдательное исследованиеПриглашаются здоровые добровольцы

Возраст от 18 до 49 · Любой пол · Обновлено 24 апр. 2026 г. · NCT05732623

Источник: ClinicalTrials.gov, данные получены 5 окт. 2026 г.. Каждая исследование устанавливает свои критерии участия; решение о включении принимает исследовательская группа.